T2-fluid attenuated inversion recovery fat-suppressed mismatch in the identification and characterization of lesions related to radiologically isolated syndrome
- PMID: 39184565
- PMCID: PMC11344588
- DOI: 10.1093/bjrcr/uaae028
T2-fluid attenuated inversion recovery fat-suppressed mismatch in the identification and characterization of lesions related to radiologically isolated syndrome
Abstract
The radiologically isolated syndrome is defined by the presence of incidentally identified T2-weighted hyperintense lesions, highly suggestive of central nervous system demyelination, following an MRI study that is performed for reasons other than for the investigation of symptoms related to multiple sclerosis (MS). These individuals also have no evidence of prior neurological symptoms associated with inflammatory demyelination and no alternative explanation for the observed MRI findings. Recently, the introduction of novel imaging techniques such as the "central vein sign" has improved lesion specificity for MS. In addition, the observation of T2-fluid attenuated inversion recovery (FLAIR) mismatch characteristics associated with gliomas and in those with MS with a higher disease burden appear to provide morphological data that relate to disease severity. The value of T2-FLAIR mismatch characteristics in discrete multi-focal lesions has not yet been well defined. Here, we present the value of a fat-suppressed T2-FLAIR sequence in the identification and characterization of T2-weighted hyperintensities resulting from inflammatory demyelination.
Keywords: MRI; T2-FLAIR mismatch; central vessel sign; fat suppressed; radiologically isolated syndrome.
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Institute of Radiology.
Conflict of interest statement
D.T.O. received personal compensation for consulting and advisory services from Biogen, Eisai, EMD Serono, Genentech, Genzyme/Sanofi, Moderna, RVL Pharmaceuticals, Inc., Zenas BioPharma, and research support from EMD Serono/Merck and Novartis. D.T.O. has issued national and international patents along with pending patents related to other developed technologies and has received royalties for intellectual property licensed by The Board of Regents of The University of Texas System. D.T.O. is the Founder of Revert Health Inc. C.L.-F. reports no disclosures.
Figures

References
-
- Lebrun-Frenay C, Kantarci O, Siva A, et al.Radiologically isolated syndrome. Lancet Neurol. 2023;22(11):1075-1086. - PubMed
-
- Lebrun-Frenay C, Kantarci O, Siva A, Sormani MP, Pelletier D, Okuda DT; 10-year RISC Study Group on Behalf of SFSEP, OFSEP. Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Ann Neurol. 2020;88(2):407-417. - PubMed
-
- Sati P, Oh J, Constable RT, et al.; NAIMS Cooperative. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016;12(12):714-722. - PubMed
-
- Patel SH, Poisson LM, Brat DJ, et al.T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res. 2017;23(20):6078-6085. - PubMed
Publication types
LinkOut - more resources
Full Text Sources